Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

• Eduardo Díaz-Rubio ,

  * E-mail: ediazrubio.hcsc@salud.madrid.org

  Affiliation Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

  ⨯
• Auxiliadora Gómez-España,

  Affiliation Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

  ⨯
• Bartomeu Massutí,

  Affiliation Department of Medical Oncology, Hospital General, Alicante, Spain

  ⨯
• Javier Sastre,

  Affiliation Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

  ⨯
• Margarita Reboredo,

  Affiliation Department of Medical Oncology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain

  ⨯
• José Luis Manzano,

  Affiliation Department of Medical Oncology, Instituto Catalán de Oncología, Hospital Germans Trias I Pujol, Badalona, Spain

  ⨯
• Fernando Rivera,

  Affiliation Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain

  ⨯
• MªJosé Safont,

  Affiliation Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain

  ⨯
• Clara Montagut,

  Affiliation Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

  ⨯
• Encarnación González,

  Affiliation Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain

  ⨯
• Manuel Benavides,

  Affiliation Department of Medical Oncology, Hospital Universitario Carlos Haya, Málaga, Spain

  ⨯
• Eugenio Marcuello,

  Affiliation Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

  ⨯
• Andrés Cervantes,

  Affiliation Department of Medical Oncology, Institute of Health Research INCLIVA. University of Valencia, Valencia, Spain

  ⨯
• Purificación Martínez de Prado,

  Affiliation Department of Medical Oncology, Hospital de Basurto, Vizcaya, Spain

  ⨯
• Carlos Fernández-Martos,

  Affiliation Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain

  ⨯
• Antonio Arrivi,

  Affiliation Department of Medical Oncology, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain

  ⨯
• Inmaculada Bando,

  Affiliation Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

  ⨯
•  [ ... ],
• Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

  Membership of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) is provided in the Acknowledgments

  Affiliation Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

  ⨯
• [ view all ]
• [ view less ]